IBRX Stock Has Quadrupled This Year – And Now The Much-Talked-About Anktiva Has Entered Saudi Arabia

• This comes just two months after ImmunityBio partnered with Biopharma and Cigalah Healthcare to launch Anktiva in the MENA region.
• The drug received approval from the Saudi Food and Drug Authority in January 2026.
• Anktiva holds approval or authorization in five regulatory jurisdictions, covering 34 countries.

ImmunityBio (IBRX) drew investor attention Tuesday after the biotech firm announced that its immunotherapy, Anktiva, is now commercially available in Saudi Arabia for patients with bladder and lung cancer, marking a significant step in its global expansion.

IBRX shares traded 4% higher in pre-market trading on Tuesday, adding to a sharp rally that has seen the stock soar around 320% so far in 2026.

Anktiva Hits Saudi Market In Just 2 Months

This comes just two months after the company announced a partnership with two healthcare commercial and distribution companies, Biopharma and Cigalah Healthcare, to launch Anktiva across the broader Middle East and North Africa (MENA) region.

The drug received approval from the Saudi Food and Drug Authority (SFDA) in January 2026. It is used with Bacillus Calmette-Guérin (BCG) to treat patients with BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma in situ, with or without papillary tumors.

It is also approved for use with a checkpoint inhibitor to treat patients with metastatic non-small cell lung cancer. ImmunityBio said that the first patients have already been identified for dosing.

Anktiva was approved by the U.S. Food and Drug Administration (FDA) in April 2024 for use with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer. It has since gained approvals in several regions, including the United Kingdom in July 2025, the European Union in February 2026, and the Macau Special Administrative Region of China in March 2026.

Anktiva Is Driving IBRX’s Revenue Story

The expansion has also led the firm to post a 168% increase in first-quarter (Q1) preliminary net product revenue at $44.2 million. Anktiva unit sales volume grew 168% year-on-year in Q1 2026.

This builds on full-year 2025 net product revenue of $113 million, a 700% jump from 2024. ImmunityBio recently highlighted that Anktiva holds approval or authorization in five regulatory jurisdictions, covering 34 countries.

How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier. Message volumes on the platform increased by more than 260% over the past 24 hours, according to Stocktwits data.

One user highlighted multiple positive updates, including ImmunityBio’s strong pipeline and Anktiva’s patent period.

However, another user said the stock’s reaction to the news was “weak” and a pullback was possible.

Read Next: ASTS Stock Climbs Overnight: Retail Bulls Don't Blink Even As Blue Origin Confirms Engine Failure Behind BlueBird-7 Miss

For updates and corrections, email newsroom[at]stocktwits[dot]com.